Tag - ELOX

Developments

Eloxx Pharma ELX-02 granted FDA orphan drug designation for cystic fibrosis

Eloxx Pharmaceuticals’ (NASDAQ:ELOX) ELX-02 received FDA orphan drug designation for the treatment of cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF transmembrane conductance...

August 5, 2020

Markets

HCW slashes Eloxx Pharma PT to $3 from $10

H.C. Wainwright slashed its price target for Eloxx Pharmaceuticals (NASDAQ:ELOX) to $3 from $10 and retained its “neutral” rating, saying the strength of the company’s ELX-02 program in cystic fibrosis is yet to be...

March 6, 2020

Markets

Janney starts Eloxx Pharma at buy; fair value estimate $14

Janney launched coverage of Eloxx Pharmaceuticals (NASDAQ:ELOX) with a “buy” rating and fair value estimate of $14. The stock closed at $5.97 on Sept. 5. Eloxx’s pipeline is focused on genetic diseases caused by...

September 6, 2019

Developments

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis. Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production...

August 6, 2019

Developments

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported that the FDA cleared its IND for a Phase 2 trial of ELX-02 in patients with cystic fibrosis (CF). ELX-02 is a small molecule designed to restore production of CF...

July 31, 2019

Tag - ELOX

Eloxx Pharma ELX-02 granted FDA orphan drug designation for cystic fibrosis

HCW slashes Eloxx Pharma PT to $3 from $10

Janney starts Eloxx Pharma at buy; fair value estimate $14

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharma IND cleared for Phase 2 cystic fibrosis trial

General

More